 |
|
Increase in Peripheral CD4 Bright+ CD8 Dull+ T Cells in Parkinson Disease
Kinya Hisanaga, MD;
Misa Asagi, MA;
Yasuto Itoyama, MD;
Yuzo Iwasaki, MD
Arch Neurol. 2001;58:1580-1583.
Background Immune abnormalities are known to be involved in the pathogenesis of
sporadic Parkinson disease.
Objective To examine whether abnormalities in peripheral lymphocytes exist in
Parkinson disease.
Methods Immune mediators, including CD1a, CD3, CD4, CD8, CD45RO, and Fas (CD95),
were examined in peripheral lymphocytes of patients by 3-color flow cytometry.
Results Patients with Parkinson disease displayed a significantly greater population
of circulating CD3+ CD4 bright+ CD8 dull+
lymphocytes than age-matched control subjects (P
= .005) and patients with cerebrovascular disease (P
= .002). The increase in these cells appeared to continue for at least 17
months. These T cells also expressed CD45RO and Fas, markers for activated
T cells, while CD1a, a marker for thymic T cells, was negative, suggesting
that these cells are mature T cells with immune activities.
Conclusions As CD4+ CD8+ T cells are known to increase after
some specific viral infections, the continuous increase in CD4 bright+ CD8 dull+ T cells shown here may indicate postinfectious
immune abnormalities that are possibly associated with the pathogenesis of
this slowly progressive, multifactorial neurodegenerative disease.
From the Departments of Neurology and Clinical Research, Miyagi National
Hospital, Miyagi, Japan (Drs Hisanaga and Iwasaki and Mr Asagi), and Department
of Neurology, Tohoku University School of Medicine, Tohoku, Japan (Dr Itoyama).
Corresponding author and reprints: Kinya Hisanaga, MD, Department
of Neurology, Miyagi National Hospital, 100 Kassenhara, Takase, Yamamoto,
Watari, Miyagi 989-2202, Japan.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Oxidative damage and cytogenic analysis in leukocytes of Parkinson's disease patients
Leblhuber et al.
Neurology 2003;60:729-729.
FULL TEXT
|
